NIH Guide for Grants and Contracts
August 02, 2019
Weekly NIH Funding Opportunities and Notices

General Notices

Notice of Changes to Funding Opportunities

Notices of Special Interest

  • Notice of Special Interest: Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Applications Directed at the Adoption of the Fast Healthcare Interoperability Resources (FHIR) Standard
    (NOT-OD-19-127)
    National Institutes of Health
    National Center for Advancing Translational Sciences
    National Center for Complementary and Integrative Health
    National Cancer Institute
    National Eye Institute
    National Human Genome Research Institute
    National Heart, Lung, and Blood Institute
    National Institute on Aging
    National Institute on Alcohol Abuse and Alcoholism
    National Institute of Allergy and Infectious Diseases
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    National Institute of Biomedical Imaging and Bioengineering
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    National Institute on Drug Abuse
    National Institute on Deafness and Other Communication Disorders
    National Institute of Dental and Craniofacial Research
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Environmental Health Sciences
    National Institute of General Medical Sciences
    National Institute of Mental Health
    National Institute on Minority Health and Health Disparities
    National Institute of Neurological Disorders and Stroke
    National Institute of Nursing Research
    National Library of Medicine

Funding Opportunities

  • NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)
    (PAR-19-319)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): October 31, 2019; March 3, 2020; June 30, 2020, October 27, 2020; March 2, 2021; June 29, 2021; October 26, 2021; March 1, 2022; June 28, 2022 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

  • Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)
    (PAR-19-320)
    National Institute of Nursing Research
    Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is October 16, 2019. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)
    (PAR-19-321)
    National Institute of Nursing Research
    Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is October 5, 2019 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    (PAR-19-325)
    National Cancer Institute
    Application Receipt Date(s): September 30, 2019; February 11, 2020; September 30, 2020; February 11, 2021; September 20, 2021; February 11, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)
    (PAR-19-326)
    John E. Fogarty International Center
    National Cancer Institute
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    National Institute on Drug Abuse
    National Institute of Mental Health
    Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below

  • Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    (PAR-19-327)
    National Institute on Drug Abuse
    Application Receipt Date(s): Applications will be accepted on a rolling basis, beginning on August 26, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date Applications are due by5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)

  • Building Resources for the Basic Biology of Aging in Health Disparities Research (R24 Clinical Trial Not Allowed)
    (RFA-AG-20-035)
    National Institute on Aging
    National Institute on Minority Health and Health Disparities
    Application Receipt Date(s): October 18, 2019 and October 19, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

  • Participant Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional)
    (RFA-CA-19-045)
    National Cancer Institute
    Application Receipt Date(s): October 30, 2019; October 30, 2020 All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this Funding Opportunity Announcement.

  • Participant Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Clinical Trial Not Allowed)
    (RFA-CA-19-046)
    National Cancer Institute
    Application Receipt Date(s): October 30, 2019; July 30, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) No late applications will be accepted for this Funding Opportunity Announcement Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)
    (RFA-CA-19-061)
    National Cancer Institute
    Application Receipt Date(s): November 20, 2019 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)
    (RFA-CA-19-062)
    National Cancer Institute
    Application Receipt Date(s): November 20, 2019 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trials Optional)
    (RFA-CA-19-063)
    National Cancer Institute
    Application Receipt Date(s): November 20, 2019 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • Catalyst Award In Diabetes, Endocrinology and Metabolic Diseases (DP1 Clinical Trial Not Allowed)
    (RFA-DK-19-014)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): December 3, 2019 by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on the listed date.

  • Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)
    (RFA-ES-19-011)
    National Institute of Environmental Health Sciences
    Application Receipt Date(s): November 1, 2019; December 2, 2019; January 2, 2020; February 3, 2020; March 2, 2020; April 1, 2020; May 1, 2020; June 1, 2020; July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; February 1, 2021; March 1, 2021; April 1, 2021; May 3, 2021; June 1, 2021; July 1, 2021; August 2, 2021; September 1, 2021; October 1, 2021; November 1, 2021; December 1, 2021; January 3, 2022; February 1, 2022; March 1, 2022; April 1, 2022; May 2, 2022; June 1, 2022; July 1, 2022; August 1, 2022; September 1, 2022; October 3, 2022, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement.

  • US Children with Perinatal HIV who were Born Internationally (R01 Clinical Trial Optional)
    (RFA-HD-20-006)
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    Application Receipt Date(s): November 14, 2019

  • The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R21 Clinical Trial Optional)
    (RFA-HD-20-007)
    Eunice Kennedy Shriver National Institute of Child Health and Human Development
    Application Receipt Date(s): November 7, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.